Top

Published in:

Open Access 18-06-2022 | Lung Cancer | Lung Cancer (TA Leal and N Sethakorn, Section Editors)

Immune Checkpoint Inhibitors and Chemoradiation for Limited-Stage Small Cell Lung Cancer

Authors: Brian Schlick, MD, Misty Dawn Shields, MD, PhD, Julian A. Marin-Acevedo, MD, Ishika Patel, Bruna Pellini, MD

Published in: Current Treatment Options in Oncology | Issue 8/2022

Opinion statement

Limited-stage small cell lung cancer (LS-SCLC) is a potentially curable disease. However, most patients develop disease relapse shortly after definitive treatment. The landmark trials IMpower133 and CASPIAN demonstrated a survival benefit with the addition of immunotherapy to first-line platinum/etoposide for extensive-stage small cell lung cancer. Therefore, it is critical to determine whether advancements in overall survival with immunotherapy can be translated earlier into the treatment paradigm for LS-SCLC. Decades of robust preclinical research into the synergism of radiation therapy and immunotherapy set the stage for the combination of these treatment modalities. Recently published data suggests tolerability of single agent immunotherapy concurrent with chemoradiation in LS-SCLC, along with promising efficacy. However, combination immunotherapy in the consolidation setting appears too toxic, although this may be reflective of the dosing schedule rather than inherent to any combination immune checkpoint blockade. Here, we review underlying mechanisms of synergy with the combination of radiation and immunotherapy, the safety and efficacy of respective treatment modalities, and the ongoing trials that are exploring novel therapeutic approaches for LS-SCLC. Pivotal trials in LS-SCLC are ongoing and anticipated to aid in understanding efficacy and safety of immunotherapy with concurrent platinum-based chemoradiotherapy.

Rudin CM, Brambilla E, Faivre-Finn C, Sage J. Small-cell lung cancer. Nat Rev Dis Primers. 2021;7(1):3.CrossRef

Waqar SN, Morgensztern D. Treatment advances in small cell lung cancer (SCLC). Pharmacol Ther. 2017;180:16–23.CrossRef

Salem A, Mistry H, Hatton M, Locke I, Monnet I, Blackhall F, Faivre-Finn C. Association of chemoradiotherapy with outcomes among patients with stage I to II vs stage III small cell lung cancer: secondary analysis of a randomized clinical trial. JAMA Oncol. 2019;5(3):e185335.CrossRef

Simone CB 2nd, et al. Radiation Therapy for small cell lung cancer: an ASTRO clinical practice guideline. Pract Radiat Oncol. 2020;10(3):158–73.CrossRef

NCCN. Small Cell Lung Cancer (Version 2.2022). 2019 [cited 2022; Available from: https://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf.

Auperin A, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med. 1999;341(7):476–84.CrossRef

Meert AP, Paesmans M, Berghmans T, Martin B, Mascaux C, Vallot F, Verdebout JM, Lafitte JJ, Sculier JP. Prophylactic cranial irradiation in small cell lung cancer: a systematic review of the literature with meta-analysis. BMC Cancer. 2001;1:5. https://doi.org/10.1186/1471-2407-1-5.CrossRefPubMedPubMedCentral

Faivre-Finn C, Snee M, Ashcroft L, Appel W, Barlesi F, Bhatnagar A, Bezjak A, Cardenal F, Fournel P, Harden S, le Pechoux C, McMenemin R, Mohammed N, O'Brien M, Pantarotto J, Surmont V, van Meerbeeck J, Woll PJ, Lorigan P, et al. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. Lancet Oncol. 2017;18:1116–25. https://doi.org/10.1016/S1470-2045(17)30318-2.CrossRefPubMedPubMedCentral

Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol. 1992;10:890–5. https://doi.org/10.1200/JCO.1992.10.6.890.CrossRefPubMed

10.

Pignon JP, Arriagada R, Ihde DC, Johnson DH, Perry MC, Souhami RL, Brodin O, Joss RA, Kies MS, Lebeau B, Onoshi T, Østerlind K, Tattersall MHN, Wagner H. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med. 1992;327:1618–24. https://doi.org/10.1056/NEJM199212033272302.CrossRefPubMed

11.

Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ, Huemer F, Losonczy G, Johnson ML, Nishio M, Reck M, Mok T, Lam S, Shames DS, Liu J, Ding B, Lopez-Chavez A, Kabbinavar F, Lin W, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379:2220–9. https://doi.org/10.1056/NEJMoa1809064.CrossRefPubMed

12.

Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Kazarnowicz A, Losonczy G, Conev NV, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394:1929–39. https://doi.org/10.1016/S0140-6736(19)32222-6.CrossRefPubMed

13.

Steel GG. Terminology in the description of drug-radiation interactions. Int J Radiat Oncol Biol Phys. 1979;5:1145–50. https://doi.org/10.1016/0360-3016(79)90634-5.CrossRefPubMed

14.

• Donlon NE, et al. Radiotherapy, immunotherapy, and the tumour microenvironment: Turning an immunosuppressive milieu into a therapeutic opportunity. Cancer Lett. 2021;502:84–96. https://doi.org/10.1016/j.canlet.2020.12.045 A review focusing on the synergism between radiation and immunotherapy, and the potential therapeutic implications.CrossRefPubMed

15.

Bentzen SM, Harari PM, Bernier J. Exploitable mechanisms for combining drugs with radiation: concepts, achievements and future directions. Nat Clin Pract Oncol. 2007;4:172–80. https://doi.org/10.1038/ncponc0744.CrossRefPubMed

16.

Jagodinsky JC, Harari PM, Morris ZS. The promise of combining radiation therapy with immunotherapy. Int J Radiat Oncol Biol Phys. 2020;108:6–16. https://doi.org/10.1016/j.ijrobp.2020.04.023.CrossRefPubMedPubMedCentral

17.

Merrick A, Errington F, Milward K, O'Donnell D, Harrington K, Bateman A, Pandha H, Vile R, Morrison E, Selby P, Melcher A. Immunosuppressive effects of radiation on human dendritic cells: reduced IL-12 production on activation and impairment of naive T-cell priming. Br J Cancer. 2005;92:1450–8. https://doi.org/10.1038/sj.bjc.6602518.CrossRefPubMedPubMedCentral

18.

Deng L, Liang H, Xu M, Yang X, Burnette B, Arina A, Li XD, Mauceri H, Beckett M, Darga T, Huang X, Gajewski TF, Chen ZJ, Fu YX, Weichselbaum RR. STING-dependent cytosolic DNA sensing promotes radiation-induced type i interferon-dependent antitumor immunity in immunogenic tumors. Immunity. 2014;41:843–52. https://doi.org/10.1016/j.immuni.2014.10.019.CrossRefPubMedPubMedCentral

19.

Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, Benci JL, Xu B, Dada H, Odorizzi PM, Herati RS, Mansfield KD, Patsch D, Amaravadi RK, Schuchter LM, Ishwaran H, Mick R, Pryma DA, Xu X, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015;520:373–7. https://doi.org/10.1038/nature14292.CrossRefPubMed

20.

Reits EA, Hodge JW, Herberts CA, Groothuis TA, Chakraborty M, K.Wansley E, Camphausen K, Luiten RM, de Ru AH, Neijssen J, Griekspoor A, Mesman E, Verreck FA, Spits H, Schlom J, van Veelen P, Neefjes JJ. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med. 2006;203:1259–71. https://doi.org/10.1084/jem.20052494.CrossRefPubMedPubMedCentral

21.

Reap EA, Roof K, Maynor K, Borrero M, Booker J, Cohen PL. Radiation and stress-induced apoptosis: a role for Fas/Fas ligand interactions. Proc Natl Acad Sci U S A. 1997;94:5750–5. https://doi.org/10.1073/pnas.94.11.5750.CrossRefPubMedPubMedCentral

22.

Mole RH. Whole body irradiation; radiobiology or medicine? Br J Radiol. 1953;26:234–41. https://doi.org/10.1259/0007-1285-26-305-234.CrossRefPubMed

23.

Abuodeh Y, Venkat P, Kim S. Systematic review of case reports on the abscopal effect. Curr Probl Cancer. 2016;40:25–37. https://doi.org/10.1016/j.currproblcancer.2015.10.001.CrossRefPubMed

24.

Garelli E, Rittmeyer A, Putora PM, Glatzer M, Dressel R, Andreas S. Abscopal effect in lung cancer: three case reports and a concise review. Immunotherapy. 2019;11:1445–61. https://doi.org/10.2217/imt-2019-0105.CrossRefPubMed

25.

Demaria S, Ng B, Devitt ML, Babb JS, Kawashima N, Liebes L, Formenti SC. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys. 2004;58:862–70. https://doi.org/10.1016/j.ijrobp.2003.09.012.CrossRefPubMed

26.

Golden EB, Chhabra A, Chachoua A, Adams S, Donach M, Fenton-Kerimian M, Friedman K, Ponzo F, Babb JS, Goldberg J, Demaria S, Formenti SC. Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial. Lancet Oncol. 2015;16:795–803. https://doi.org/10.1016/S1470-2045(15)00054-6.CrossRefPubMed

27.

Jie Y, Gu A, Fu P, Kong FMS. Does radiation increase the risk of immunotherapy related pneumonitis in cancer patients with thorax radiotherapy combined immune checkpoint inhibitors: A meta-analysis. J Clin Oncol. 2020;38:e15099. https://doi.org/10.1200/JCO.2020.38.15_suppl.e15099.CrossRef

28.

Pakkala S, Higgins K, Chen Z, Sica G, Steuer C, Zhang C, Zhang G, Wang S, Hossain MS, Nazha B, Beardslee T, Khuri FR, Curran W, Lonial S, Waller EK, Ramalingam S, Owonikoko TK. Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study. J Immunother Cancer. 2020;8:e001302. https://doi.org/10.1136/jitc-2020-001302.CrossRefPubMedPubMedCentral

29.

Shaverdian N, Lisberg AE, Bornazyan K, Veruttipong D, Goldman JW, Formenti SC, Garon EB, Lee P. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol. 2017;18:895–903. https://doi.org/10.1016/S1470-2045(17)30380-7.CrossRefPubMedPubMedCentral

30.

Theelen WSME, Peulen HMU, Lalezari F, van der Noort V, de Vries JF, Aerts JGJV, Dumoulin DW, Bahce I, Niemeijer ALN, de Langen AJ, Monkhorst K, Baas P. Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non–small cell lung cancer: results of the PEMBRO-RT phase 2 randomized clinical trial. JAMA Oncol. 2019;5:1276–82. https://doi.org/10.1001/jamaoncol.2019.1478.CrossRefPubMedPubMedCentral

31.••

Peters S, et al. Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy - results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial. Ann Oncol. 2022;33:67–79. https://doi.org/10.1016/j.annonc.2021.09.011 The second published trial examining immunotherapy in LS-SCLC. This trial used combination ICI in the consolidation setting, which led to excessive toxicity.

32.

Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, Park K, Alexandru A, Lupinacci L, de la Mora Jimenez E, Sakai H, Albert I, Vergnenegre A, Peters S, Syrigos K, Barlesi F, Reck M, Borghaei H, Brahmer JR, et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med. 2019;381(21):2020–31.CrossRef

33.

NCCN. Non-Small Cell Lung Cancer. 2021; Available from: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf.

34.

Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, et al. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017;377:1919–29. https://doi.org/10.1056/NEJMoa1709937.CrossRefPubMed

35.

Atezolizumab after concurrent chemo-radiotherapy versus chemo-radiotherapy alone in limited disease small-cell lung cancer. https://ClinicalTrials.gov/show/NCT03540420.

36.

Study of durvalumab + tremelimumab, durvalumab, and placebo in limited stage small-cell lung cancer in patients who have not progressed following concurrent chemoradiation therapy. https://ClinicalTrials.gov/show/NCT03703297.

37.

A study of atezolizumab with or without tiragolumab consolidation in limited stage small cell lung cancer. https://clinicaltrials.gov/ct2/show/NCT04308785.

38.

•• Welsh JW, et al. Phase 1/2 trial of pembrolizumab and concurrent chemoradiation therapy for limited-stage SCLC. J Thorac Oncol. 2020;15:1919–27. https://doi.org/10.1016/j.jtho.2020.08.022 The first published trial examining immunotherapy in LS-SCLC. This trial shows the promise of adding single agent immunotherapy concurrent to chemoradiation.CrossRefPubMed

39.

Martin Reck, Delvys Rodríguez-Abreu, Andrew G Robinson, Rina Hui, Tibor Csőszi, Andrea Fülöp, Maya Gottfried, Nir Peled, Ali Tafreshi, Sinead Cuffe, Mary O'Brien, Suman Rao, Katsuyuki Hotta, Melanie A Leiby, Gregory M Lubiniecki, Yue Shentu, Reshma Rangwala, Julie R Brahmer, KEYNOTE-024 Investigators. Pembrolizumab versus chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. Clinical Trial N Engl J Med. 2016;10:375(19):1823–1833. https://doi.org/10.1056/NEJMoa1606774. Epub 2016 Oct 8.

40.

Testing the addition of a new immunotherapy drug, atezolizumab (MPDL3280A), to the usual chemoradiation (CRT) therapy treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC). https://ClinicalTrials.gov/show/NCT03811002.

41.

Rimner A, Lai WVV, Califano R, Jabbour SK, Faivre-Finn C, Cho BC, Kato T, Yu J, Yu L, Zhao B, Pietanza MC, Byers LA. KEYLYNK-013: A phase 3 study of pembrolizumab in combination with concurrent chemoradiation therapy followed by pembrolizumab with or without olaparib versus concurrent chemoradiation therapy in patients with newly diagnosed limited-stage SCLC. J Clin Oncol. 2021;39:TPS8587. https://doi.org/10.1200/JCO.2021.39.15_suppl.TPS8587.CrossRef

42.

Efficacy and safety of standard of care plus durvalumab in patients with limited disease small cell lung cancer (DOLPHIN). https://ClinicalTrials.gov/show/NCT04602533.

43.

Efficacy and safety of SHR-1316 in combination with chemo-radiotherapy in patients with LS-SCLC. https://clinicaltrials.gov/ct2/show/NCT04691063.

44.

Chemoradiation with durvalumab followed by durvalumab maintenance for limited disease small cell lung cancer. https://www.clinicaltrials.gov/ct2/show/NCT03585998.

45.

Owonikoko TK, Park K, Govindan R, Ready N, Reck M, Peters S, Dakhil SR, Navarro A, Rodríguez-Cid J, Schenker M, Lee JS, Gutierrez V, Percent I, Morgensztern D, Barrios CH, Greillier L, Baka S, Patel M, Lin WH, et al. Nivolumab and ipilimumab as maintenance therapy in extensive-disease small-cell lung cancer: CheckMate 451. J Clin Oncol. 2021;39:1349–59. https://doi.org/10.1200/JCO.20.02212.CrossRefPubMedPubMedCentral

46.

Senan S, Okamoto I, Lee GW, Chen Y, Niho S, Mak G, Yao W, Shire N, Jiang H, Cho BC. Design and rationale for a phase III, randomized, placebo-controlled trial of durvalumab with or without tremelimumab after concurrent chemoradiotherapy for patients with limited-stage small-cell lung cancer: the ADRIATIC study. Clin Lung Cancer. 2020;21(2):e84–8.CrossRef

47.

Johnson ML. Durvalumab +/- tremelimumab + chemotherapy as first-line tratment for mNSCLC: results from the phase 3 POSEIDON study. In: World Lung. 2021.

48.

Tachihara M, Tsujino K, Ishihara T, Hayashi H, Sato Y, Kurata T, Sugawara S, Okamoto I, Teraoka S, Azuma K, Daga H, Yamaguchi M, Kodaira T, Satouchi M, Shimokawa M, Yamamoto N, Nakagawa K, members of the West Japan Oncology Group (WJOG). Rationale and Design for a Multicenter, Phase II Study of Durvalumab Plus Concurrent Radiation Therapy in Locally Advanced Non-Small Cell Lung Cancer: The DOLPHIN Study (WJOG11619L). Cancer Manag Res. 2021;13:9167–73.CrossRef

49.

Ross HJ, et al. NRG Oncology/Alliance LU005: A phase II/III randomized clinical trial of chemoradiation versus chemoradiation plus atezolizumab in limited stage small cell lung cancer. J Clin Oncol. 2020;38(15_suppl):TPS9082.CrossRef

50.

Durvalumab with chemotherapy followed by sequential radiotherapy for limited stage small cell lung cancer. https://clinicaltrials.gov/ct2/show/NCT05034133.

51.

Study of ociperlimab plus tislelizumab plus chemoradiotherapy in participants with untreated limited-stage small cell lung cancer. https://ClinicalTrials.gov/show/NCT04952597.

52.

Byers LA, Wang J, Nilsson MB, Fujimoto J, Saintigny P, Yordy J, Giri U, Peyton M, Fan YH, Diao L, Masrorpour F, Shen L, Liu W, Duchemann B, Tumula P, Bhardwaj V, Welsh J, Weber S, Glisson BS, et al. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov. 2012;2(9):798–811.CrossRef

53.

Sen T, Rodriguez BL, Chen L, Corte CMD, Morikawa N, Fujimoto J, Cristea S, Nguyen T, Diao L, Li L, Fan Y, Yang Y, Wang J, Glisson BS, Wistuba II, Sage J, Heymach JV, Gibbons DL, Byers LA. Targeting DNA damage response promotes antitumor immunity through STING-Mediated T-cell activation in small cell lung cancer. Cancer Discov. 2019;9:646–61. https://doi.org/10.1158/2159-8290.CD-18-1020.CrossRefPubMedPubMedCentral

54.

Thomas A, Vilimas R, Trindade C, Erwin-Cohen R, Roper N, Xi L, Krishnasamy V, Levy E, Mammen A, Nichols S, Chen Y, Velcheti V, Yin F, Szabo E, Pommier Y, Steinberg SM, Trepel JB, Raffeld M, Young HA, et al. Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II Study. J Thorac Oncol. 2019;14:1447–57. https://doi.org/10.1016/j.jtho.2019.04.026.CrossRefPubMedPubMedCentral

55.

Krebs M, Ross K, Kim S, et al. P1.15-004 an open-label, multitumor phase II basket study of olaparib and durvalumab (MEDIOLA): results in patients with relapsed SCLC. J Thorac Oncol. 2017:12. https://doi.org/10.1016/j.jtho.2017.09.1040.

56.

Ge Z, Peppelenbosch MP, Sprengers D, Kwekkeboom J. TIGIT, the next step towards successful combination immune checkpoint therapy in cancer. Front Immunol. 2021;12:699895. https://doi.org/10.3389/fimmu.2021.699895.CrossRefPubMedPubMedCentral

57.

Rodriguez-Abreu D, Johnson ML, Hussein MA, Cobo M, Patel AJ, Secen NM, Lee KH, Massuti B, Hiret S, Yang JCH, Barlesi F, Lee DH, Paz-Ares LG, Hsieh RW, Miller K, Patil N, Twomey P, Kapp AV, Meng R, Cho BC. Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE). J Clin Oncol. 2020;38:9503. https://doi.org/10.1200/JCO.2020.38.15_suppl.9503.CrossRef

58.

SHR-1316 maintenance therapy for limited stage small cell lung cancer. https://clinicaltrials.gov/ct2/show/NCT04647357.

59.

Chemoradiotherapy with or without sintilimab in limited-stage SCLC. https://clinicaltrials.gov/ct2/show/NCT04189094.

60.

Toripalimab for limited-stage small cell lung cancer following concurrent chemoradiotherapy. https://clinicaltrials.gov/ct2/show/NCT04418648.

Title: Immune Checkpoint Inhibitors and Chemoradiation for Limited-Stage Small Cell Lung Cancer
Authors: Brian Schlick, MD
Misty Dawn Shields, MD, PhD
Julian A. Marin-Acevedo, MD
Ishika Patel
Bruna Pellini, MD
Publication date: 18-06-2022
Publisher: Springer US
Keywords: Lung Cancer
Lung Cancer
SCLC
Lung Cancer
SCLC
Checkpoint Inhibitors
Published in: Current Treatment Options in Oncology / Issue 8/2022
Print ISSN: 1527-2729
Electronic ISSN: 1534-6277
DOI: https://doi.org/10.1007/s11864-022-00989-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Opinion statement

Please log in to get access to this content

Other articles of this Issue 8/2022

Incorporating Molecular Diagnostics into Treatment Paradigms for Endometrial Cancer

Correction to: Cardiotoxicity of Systemic Melanoma Treatments

Metastatic Adenoid Cystic Carcinoma: Genomic Landscape and Emerging Treatments

How Genetics Can Drive Initial Therapy Choices for Older Patients with Acute Myeloid Leukemia

The Role of Immunotherapy in the Treatment of Anal Cancer and Future Strategies

Keynote webinar | Spotlight on antibody–drug conjugates in cancer